Decision: Favourable

Study Title:

A Phase 3, Randomized, Placebo-Controlled, Double-Blind,Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Dr Dearbhaile Collins

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    Karyopharm Therapeutics Inc.,

Scroll to Top
Skip to content